We recently compiled a list of the 10 Best Non-Tech Stocks to Buy Now for Long Term. In this article, we are going to take a ...

恩考拉非尼、西妥昔单抗和 mFOLFOX6 的组合疗法已获得 FDA 的加速批准，用于治疗患有 BRAF V600E 突变的转移性结直肠癌患者。 美国食品药品监督管理局（FDA）加速批准恩科拉非尼（Braftovi，辉瑞公司子公司 Array ...

The leading Metastatic Pancreatic Cancer Companies such as Xencor, MEI Pharma, Celldex Therapeutics, TG Therapeutics, ...

Ronald E. Blaylock, a director at Pfizer Inc. (NYSE:PFE), purchased 19,457 shares of the company's common stock. The ...

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed ...

Among patients with metastatic colorectal cancer (mCRC) harboring BRAF V600E mutations, treatment with the combination of Braftovi (encorafenib), Erbitux (cetuximab), and mFOLFOX6 (fluorouracil, ...

Significant and clinically relevant improvement seen in objective response rate with encorafenib + cetuximab plus mFOLFOX6. HealthDay News — For patients with BRAF V600E-mutant metastatic colorectal ...

Pfizer PFE announced positive top-line results from the progression-free survival (PFS) analysis of a late-stage study of its oncology drug, Braftovi (encorafenib), for treating patients with ...

Braftovi was a combination with Lilly’s Erbitux for adults with mCRC with a BRAF V600E mutation after prior therapy. The BREAKWATER study data is being reviewed by global regulatory authorities ...

Pfizer has announced that its Braftovi (encorafenib) regimen significantly improved both progression-free and overall survival in a late-stage colorectal cancer (CRC) study.

Pfizer Inc. (NYSE: PFE) today announced positive topline results from the progression-free survival (PFS) analysis of the Phase 3 BREAKWATER study of ...